RxDoctor Payments Data

Tina McKennon

Adult Health · Cherry Hill, NJNPI 1992163422

Payments from drug & device makers

$2,453in general payments, 2019–2025

Across 33 payments — averaging $74.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$562
  • Pharmacosmos Therapeutics Inc.$288
  • Novocure Inc.$279
  • Amgen$261
  • Johnson & Johnson$213
  • Bayer$194
  • plus $656 from 8 others

What the payments were for

  • Food & beverage$2,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,453 in reported general payments places this provider in the 85th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$71,675
Medicare patients
218
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide61$1,035,903
IbrancePalbociclib59$929,705
ImbruvicaIbrutinib44$640,928
Lenalidomide45$578,393
PomalystPomalidomide26$540,985
LynparzaOlaparib42$532,354
CalquenceAcalabrutinib Maleate25$277,972
EliquisApixaban79$76,850
Abiraterone Acetate15$61,573
PegasysPeginterferon Alfa-2a13$51,205
OrgovyxRelugolix13$31,864
XareltoRivaroxaban19$20,323
Deferasirox12$11,725
Hydroxyurea49$1,397
Letrozole46$1,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$16$1,035,90361 claims
AstraZenecaLynparza, Calquence$126$810,32767 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$562$540,98526 claims
Johnson & JohnsonXarelto$213$20,32319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →